Topics

Antibody-Based Immunotherapy And Targeted Immune Activation

Cancer Immunotherapy

Antibody-based immunotherapy uses monoclonal antibodies and antibody derivatives to target selected immune response components in cancer treatment[1]. It includes immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, and bispecific T-cell engagers[1]. The field moved from conventional antibody targeting toward active immune redirection because T-cell activation and inhibition of suppressive immune mechanisms are now central therapeutic goals[1][2].

Targeted immune activation works by blocking inhibitory immune checkpoints or physically linking immune effector cells to tumor cells[2][3]. CTLA-4, PD-1, and PD-L1 are widely studied immune checkpoint targets, and antibodies against these pathways restore antitumor immune activity by interfering with suppressive signaling[2][3]. Ipilimumab improved overall survival in previously treated metastatic melanoma, showing that checkpoint blockade can produce clinically meaningful immune activation[3]. Blinatumomab redirects CD3-positive T cells against CD19-positive leukemia cells and produced longer overall survival than chemotherapy in advanced acute lymphoblastic leukemia[4].

Antibody-drug conjugates extend targeted therapy by coupling antibody recognition to cytotoxic payload delivery[1][5]. Trastuzumab deruxtecan showed durable antitumor activity in previously treated HER2-positive metastatic breast cancer, supporting HER2-directed antibody-drug conjugates as a major disease application[5]. Bispecific antibodies recognize two antigens or epitopes and can combine immune-cell engagement, checkpoint inhibition, or non-checkpoint targeting in one engineered molecule[6][7]. These formats are being evaluated in hematologic malignancies, breast cancer, melanoma, and treatment-resistant solid tumors[1][5][6][7].

Current gaps include resistance, immune-related adverse events, on-target/off-tumor activity, and uncertainty over optimal target pairing[6][7][8]. Bispecific strategies that target PD-L1 and TGF-β address two immunosuppressive pathways that contribute to cancer immune evasion[8]. Future development should prioritize biomarker-guided patient selection, safer immune activation, rational antibody engineering, and combination regimens that preserve antitumor efficacy while limiting toxicity[6][7][8].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-D1738 DAPI dilactate
DAPI (4',6-Diamidino-2-phenylindole) dilactate is a DAPI dye. DAPI is a fluorescent dye that binds strongly to DNA. It binds to the AT base pair of the double-stranded DNA minor groove, and one DAPI molecule can occupy three base pair positions. The fluorescence intensity of DAPI molecules bound to double-stranded DNA is increased by about 20 times, and it is commonly observed with fluorescence microscopy, and the amount of DNA can be determined based on the intensity of fluorescence. DAPI cannot penetrate intact cell membranes and is commonly used for staining damaged and fixed cells. DAPI (Compound 3) is an acid-sensing ion channel 3 (ASIC3) inhibitor. DAPI binds to ASIC3 and blocks the channel function. DAPI can be used in the study of chronic pain treatment (Ex/Em = 356/451 nm).
Fluorescent Dye  
178
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-L004 Cell Cycle/DNA Damage Compound Library
DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair. MCE owns a unique collection of 3,522 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Signaling Pathway Targeting Libraries

93
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L181 Bioactive Compound Library Max
Bioactive small molecules are important sources of lead compounds and effective tools for drug screening. Because the target of active small molecules is clear, it is conducive to the study of mechanism. In addition, due to the large structural differences between the individual active molecules, it is easier to obtain a greater variety of lead compounds. MCE integrates the Bioactive Compound Library (HY-L001) and Novel Bioactive Compound Library (HY-L111) to form the Bioactive Compound Library Max. Bioactive Compound Library Max contains novel active small molecules, molecules that have entered the clinical stage and the market, and small molecules that have been verified by cell experiments or biochemical experiments, which fundamentally expands the number of compound libraries in the library and improves the structural diversity, and is an effective tool to start drug screening and mechanism research. MCE can provide a library of 30,147 mitophagy compounds, which can be used for drug development and mechanism research in cancer, immunity, infection and other hot research fields.

General Bioactive Screening Libraries

85
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L180 Mitophagy Compound Library
Mitochondrial autophagy refers to the selective encapsulation and degradation of damaged mitochondria by cells through the autophagy mechanism, thereby maintaining mitochondrial and cellular homeostasis. The concept of mitochondrial autophagy has received extensive attention since it was proposed. Current studies have shown that the mechanisms of mitochondrial autophagy can generally be divided into two categories: Ubiquitin-dependent pathways and Ub-independent pathways. In addition, mitochondrial autophagy is a research hotspot related to the pathogenesis of neurodegenerative diseases, cardiovascular diseases, cancer, metabolic diseases and other clinical diseases. Therefore, high-throughput screening based on mitochondrial autophagy can effectively screen out compounds that are closely related to the occurrence of diseases and analyze their mechanisms. MCE can provide a library of 655 mitophagy compounds, which can be used for drug development and mechanism research in cancer, immunity, infection and other hot research fields.

Signaling Pathway Targeting Libraries

84
HY-L182 Fatty Acids Compound Library
Fatty acids (FAs) are the main components of lipids. The synthesis of fatty acids mainly involves the Triglyceride (TG) cycle and De Novo Lipogenesis (DNL). Fatty acids which exist widely in organisms are components of cell membranes and play an indispensable role in cell signaling. In addition, FFAs can be taken up from circulating plasma by all mitochondria-containing cells, and they are metabolized by β-oxidation and the citric acid cycle to release large amounts of energy in the form of ATP. Abnormal fatty acid metabolism is associated with the occurrence and development of cardiovascular diseases, diabetes, fatty liver, hyperthyroidism, and other diseases. MCE offers a unique collection of fatty acid compounds. Fatty Acids Compound Library is an important tool for the study of energy metabolism and drug development of metabolism-related diseases.

Structure Classified Libraries

84
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L148 TCA Cycle Compound Library
The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins. For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future. MCE supplies a unique collection of 72 compounds related to the TCA cycle. MCE TCA Cycle Compound Library is a useful tool for the TCA cycle related research and anti-cancer drug development.

Signaling Pathway Targeting Libraries

83
HY-L177 Antibody Inhibitor Library
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases. MCE can provide 1,949 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Compound Characteristic Classified Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L227 Amino Acid Metabolite Compound Library
Amino acids are the fundamental components that sustain life activities, playing roles in ATP generation, promoting nucleotide synthesis, and maintaining cellular redox balance. Moreover, dysregulation of amino acid consumption is a significant potential regulatory mechanism leading to impaired anti-tumor immunity in immune cells. The normal functioning of immune cells relies on amino acid metabolic pathways to obtain energy and materials, and upon activation, they reprogram their metabolism to support growth, proliferation, and effector functions. Additionally, metabolic disorders of specific amino acids (such as branched-chain amino acids, glutamine, and arginine) can exacerbate mitochondrial dysfunction and oxidative stress, thereby promoting myocardial fibrosis and cardiac cell damage. Therefore, conducting research related to amino acid metabolism holds promise for discovering potential drugs for diseases related to cancer, immunity, and metabolism. MCE can provide 194 kinds of metabolites of amino acid metabolic pathways, which can be used for drug screening in various diseases such as cancer, immune disorders, metabolic diseases, mitochondrial-targeted diseases

Metabolism Focused Libraries

83
HY-L231 TCA Cycle Metabolite Compound Library
The TCA cycle (tricarboxylic acid cycle)—is also known as the Krebs cycle or the citric acid cycle (CAC). The TCA cycle is a series of chemical reactions that release stored energy through the oxidation of acetyl-CoA in carbohydrates, fats, and proteins. For decades, the TCA cycle has been considered as the central pathway for cell oxidative phosphorylation to produce energy and biosynthesis. Research shows that TCA cycle is associated with many diseases, especially cancer. In colon carcinoma, liver cancer and other cancers, there are mutations that lead to the imbalance of TCA cycle metabolites, indicating that TCA cycle may be related to the occurrence of cancer. Understanding the role and molecular mechanism of TCA cycle in inhibiting or promoting cancer progression will promote the development of new metabolite-based cancer treatment methods in the future. MCE supplies a unique collection of 25 key intermediates of the TCA cycle, which can be utilized for TCA-related research and metabolomics identification studies.
83
HY-L264 DNA Damage Repair Inhibitor Library
DNA damage response (DDR) is a fundamental mechanism for maintaining genomic stability. When DNA damage occurs, such as single- or double-strand breaks or replication fork stalling, cells rely on key proteins including ATM, ATR, PARP, and DNA-PK to sense the damage and transmit signals, thereby regulating DNA repair, cell-cycle arrest, and cell death. Inhibition of specific DNA repair or checkpoint pathways can prevent tumor cells from effectively repairing accumulated DNA damage, ultimately leading to tumor cell death. MCE DNA Damage Repair Inhibitor Library contains 0 compounds, focusing on key nodes involved in DNA damage response and DNA repair. The library covers multiple DNA repair and cell-cycle checkpoint pathways, providing a systematic compound screening tool for research on precision oncology, synthetic lethality, drug resistance mechanisms, and chemo- or radiosensitization.
83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-D0952 Acridine Orange base
Acridine Orange base is a cell-permeable fluorescent dye that stains organisms (bacteria, parasites, viruses, etc.) bright orange and, when used under appropriate conditions (pH=3.5, Ex=460 nm), distinguishes human cells in green for detection by fluorescence microscopy. Acridine Orange base fluoresces green when bound to dsDNA (Ex=488, Em=520-524) and red when bound to ssDNA (Ex=457, Em=630-644) or ssRNA (Ex=457, Em=630-644), also can be used in cell cycle assays.
Parasite  
44
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-K1071 Cell Cycle and Apoptosis Analysis Kit (PI staining)

MCE Cell Cycle and Apoptosis Analysis Kit (PI staining) provides a convenient method to detect cell cycle and cell apoptosis.


Cell Biology Cell Analysis Cell Apoptosis and Necrosis

31
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-B1352 L-Ornithine
L-Ornithine ((S)-2,5-Diaminopentanoic acid) is a non-proteinogenic amino acid, is mainly used in urea cycle removing excess nitrogen in vivo. L-Ornithine shows nephroprotective.
Arginase   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   SARS-CoV-2 Infection  
10
HY-107780A Cyclic-di-GMP sodium
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research.

Source: bacterial species

STING   Endogenous Metabolite  
9
HY-107780 Cyclic-di-GMP
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.

Source: bacterial species

STING   Endogenous Metabolite  
9
HY-107780B Cyclic-di-GMP diammonium
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research.
STING   Endogenous Metabolite  
Cancer   Bacterial Infection  
9
HY-110382 Cyclic-di-GMP disodium
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
STING   Endogenous Metabolite  
9
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-128851A Coenzyme A trilithium
Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
Endogenous Metabolite   Fatty Acid Synthase (FASN)  
Cancer   Metabolic or Endocrine Disease  
6
HY-128851B Coenzyme A sodium
Coenzyme A (CoASH) sodium is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
Endogenous Metabolite   Fatty Acid Synthase (FASN)  
Cancer   Metabolic or Endocrine Disease  
6
HY-N0636 Eriocitrin
Eriocitrin is a flavonoid isolated from lemons that is a powerful antioxidant. Eriocitrin inhibits the proliferation of liver cancer cells by arresting the cell cycle in the S phase by upregulating p53, cyclin A, cyclin D3 and CDK6. Eriocitrin triggers apoptosis by activating intrinsic signaling pathways involving mitochondria.
Apoptosis  
Liver Cancer   Digestive System Inflammation  
6
HY-128851 Coenzyme A
Coenzyme A (CoASH) is a ubiquitous and essential cofactor, which is an acyl group carrier and carbonyl-activating group for the citric acid cycle and fatty acid metabolism. Coenzyme A plays a central role in the oxidation of pyruvate in the citric acid cycle and the metabolism of carboxylic acids, including short- and long-chain fatty acids.
Endogenous Metabolite   Fatty Acid Synthase (FASN)  
Ovarian Cancer   Lipid Metabolism  
6
HY-P9901 Ipilimumab
Ipilimumab is a fully human monoclonal antibody IgG1κ that blocks the inhibitory receptor cytotoxic T lymphocyte antigen 4 (CTLA-4) on T cells. Ipilimumab can be used in unresectable or metastatic melanoma (MM) studies.

Species: Human

CTLA-4  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Metastatic Melanoma  
5
HY-D1098A SYBR Green II (Ionic form)
SYBR Green II (Ionic form) is a fluorescent nucleic acid dye that mainly binds single-stranded nucleotides. SYBR Green II is sensitive to oligonucleotides or larger nucleic acid polymers in a variety of cells and gels. SYBR Green II can be used to study cell structure, membrane integrity or function, and cell cycle distribution. Wavelength 484/515 nm.
Fluorescent Dye  
3
HY-D1098 SYBR Green II
SYBR Green II is a fluorescent nucleic acid dye that mainly binds single-stranded nucleotides. SYBR Green II is sensitive to oligonucleotides or larger nucleic acid polymers in a variety of cells and gels. SYBR Green II can be used to study cell structure, membrane integrity or function, and cell cycle distribution. Wavelength 484/515 nm.
Fluorescent Dye  
3
HY-108829A Abatacept (powder)
Abatacept (CTLA4lg; BMS-188667) powder is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept powder is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-P99132 Anti-Mouse CTLA-4 Antibody (9D9)
Anti-Mouse CTLA-4 Antibody (9D9) is an anti-mouse CTLA-4 IgG2b monoclonal antibody. Anti-Mouse CTLA-4 Antibody (9D9) can bind to CTLA-4 and block its binding to B7. Anti-Mouse CTLA-4 Antibody (9D9) enhances T cell function by increasing the ratio of CD8+ T cells to regulatory T cells (Tregs). Anti-Mouse CTLA-4 Antibody (9D9) can be used for research on cancer such as colon cancer and melanoma.

Species: Mouse

CTLA-4  
Inflammation or Immune System Disease   Colorectal Cancer   Melanoma  
3
HY-108829 Abatacept
Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

Species: Human

CTLA-4  
Lung Cancer   Melanoma   SARS-CoV-2 Infection   Rheumatoid Arthritis  
3
HY-W127705 Quinacrine mustard dihydrochloride
Quinacrine mustard dihydrochloride is a fluorochrome. Quinacrine mustard dihydrochloride as a polycyclic aromatic agent can be used as mutagenic agent induces the mutants of bacteria. Quinacrine mustard dihydrochloride induces cell cycle arrest at G2/M-phase. Quinacrine mustard dihydrochloride has the potential for the research of plant, animal, or human chromosomes.
Fluorescent Dye  
2
HY-119109 Laminaran
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.

Source: Eisenia Bicyclis

Environmental Pollutants   C-type Lectin-like Receptors (CTLRs)   Endogenous Metabolite  
Colorectal Cancer  
2
HY-W009362 DL-Isocitric acid trisodium salt
DL-Isocitric acid trisodium salt is an endogenous metabolite. DL-Isocitric acid trisodium salt is an intermediate product in the citric acid cycle. DL-Isocitric acid trisodium salt can be used as a marker for determining the composition of isocitrates in fruit products.
Endogenous Metabolite  
Cardiovascular Disease  
2
HY-W010382 Oxaloacetic acid
Oxaloacetic acid (2-Oxosuccinic acid) is a metabolic intermediate involved in several ways, such as citric acid cycle, gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, and fatty acid synthesis, whereby Oxaloacetic acid facilitates the clearance of reactive oxygen species (ROS) and improves mitochondrial function.
Endogenous Metabolite   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-Y0808 Dimethyl succinate
Dimethyl succinate is an orally active cell permeable succinate analogue. Dimethyl succinate can disrupt the TCA cycle by elevating intracellular succinate levels, leading to reduced protein synthesis and impairs myogenic differentiation. Dimethyl succinate can induce apoptosis. Dimethyl succinate can decrease maximal cellular respiration and reserve capacity. Dimethyl succinate can rescue synapse loss in AD. Dimethyl succinate can be used for the researches of metabolic and neurological disease.
Environmental Pollutants   Apoptosis  
Metabolic or Endocrine Disease   Alzheimer's Disease  
2
HY-19554 MM-401
MM-401 is a MLL1 H3K4 methyltransferase inhibitor. MM-401 inhibits MLL1 activity (IC50 = 0.32 μM) by blocking MLL1-WDR5 interaction. MM-401 can induce cell cycle arrest, apoptosis and differentiation. MM-401 can be used for the research of MLL leukemia.
WDR5   Apoptosis  
Cancer  
1
HY-W010382S Oxaloacetic acid-13C4
Oxaloacetic acid-13C4 is the 13C-labeled Oxaloacetic acid. Oxaloacetic acid (2-Oxosuccinic acid) is a metabolic intermediate involved in several ways, such as citric acid cycle, gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, and fatty acid synthesis.
Endogenous Metabolite   Isotope-Labeled Compounds  
Metabolic or Endocrine Disease  
1
HY-N5084 Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
TRP Channel   HDAC   p38 MAPK   JNK   ERK   NF-κB   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Bladder Cancer   Pain  
1
HY-N1986 Cucurbitacin D
Cucurbitacin D is the active ingredient in Trichosanthes kirilowii and can disrupt the interaction between Hsp90 and two co-chaperones, Cdc37 and p23. Cucurbitacin D is an inflammasome activator. Cucurbitacin D induces cell cycle arrest and cell apoptosis, exhibiting anti-tumor and anti-inflammatory effects.
HSP   Apoptosis  
Digestive System Disease   Prostate Cancer   Digestive System Inflammation  
1
HY-W017018S4 L-Ornithine-d7 hydrochloride
L-Ornithine-d7 hydrochloride is the d7-labeled L-Ornithine hydrochloride (HY-W017018). L-Ornithine hydrochloride is an orally active CaSR and p38 activator. L-Ornithine hydrochloride inhibits ROS and supports urea cycle function. L-Ornithine hydrochloride can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.
Isotope-Labeled Compounds   CaSR   p38 MAPK   Reactive Oxygen Species (ROS)  
Urogenital Disease   Anxiety or Fear-Related Disease  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-121426 BPP
BPP is an cyclization-based fluorescent probe for imaging native HOBr in live cells and zebrafish.
Fluorescent Dye  
/
HY-P1126 Dolastatin 15
Dolastatin 15 (DLS 15), a depsipeptide derived from Dolabella auricularia, is a potent antimitotic agent structurally related to the antitubulin agent Dolastatin 10. Dolastatin 15 induces cell cycle arrest and apoptosis in multiple myeloma cells. Dolastatin 15 can be used as an ADC cytotoxin.
Microtubule/Tubulin   ADC Payloads   Apoptosis  
/
HY-164107 Auristatin S
Auristatin S is a potent Auristatin payload. Auristatin S binds to the vinca-binding site on tubulin, thereby inhibiting microtubule assembly and inducing cell cycle arrest and apoptosis. Auristatin S acts as a cytotoxic component of antibody-drug conjugates (ADCs) and exerts target-specific cytotoxicity against cancer cells. Auristatin S can be used in the research of lymphoma, anaplastic large cell lymphoma and Hodgkin lymphoma.
ADC Payloads   Microtubule/Tubulin   Apoptosis  
Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-Y1311G Malic acid (GMP)
Malic acid (GMP) is Malic acid (HY-Y1311) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. Malic acid (Hydroxybutanedioic acid) is a dicarboxylic acid that occurs naturally in fruits like apples and pears with oral activities. Malic acid plays a role in many sour or tangy foods. Malic acid is an intermediate in the citric acid cycle.
Endogenous Metabolite  
/
HY-P10819 S9-CMC1 TFA
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models.
Histone Demethylase   Apoptosis  
/
HY-W013636AG 2-Ketoglutaric acid Sodium (GMP)
2-Ketoglutaric acid (Alpha-Ketoglutaric acid) Sodium (GMP) is 2-Ketoglutaric acid Sodium (HY-W013636A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 2-Ketoglutaric acid Sodium is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid Sodium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid Sodium is a reversible inhibitor of tyrosinase (IC50=15 mM).
Tyrosinase   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-Y0850U8 PVA (Mw 47000, 98-99% hydrolyzed, ~1000 polymerization)
PVA (Polyvinyl alcohol; Poly(Ethenol)) (Mw 47000, 98-99% hydrolyzed, ~1000 polymerization) is a semicrystalline synthetic polymer with excellent biocompatibility and biodegradability, which is non-toxic and non-mutagenic upon oral administration in the human body. PVA (Mw 47000, 98-99% hydrolyzed, ~1000 polymerization) can serve as an excipient, inhibitor or coating agent to prepare solid dispersions by absorbing water and inhibiting drug crystal nucleation and growth, and can encapsulate insulin-like growth factor-1. PVA (Mw 47000, 98-99% hydrolyzed, ~1000 polymerization) can form physically crosslinked cryogels and degradable films, and is widely used in the construction of vascular grafts, the synthesis of articular cartilage, and studies on dry or minimally invasive ex vivo wounds. PVA (Mw 47000, 98-99% hydrolyzed, ~1000 polymerization) also promotes hydrogen peroxide generation and enhances the redox cycle of iron species, thus acting as a sacrificial agent to effectively degrade pollutants.
Biochemical Assay Reagents  
/
HY-P1813 PSA1 (141-150)
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
Prostaglandin Receptor  
/
HY-P992518 Pumitamig (Mouse IgG2a)
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P992291 Anti-PL2L60 Antibody (KAO3)
Anti-PL2L60 Antibody (KAO3) is a PL2L60-targeting antibody. Anti-PL2L60 Antibody (KAO3) binds to PL2L60 expressed on tumor cell surfaces, blocking its tumor-promoting functions. Anti-PL2L60 Antibody (KAO3) arrests tumor cell cycle and induces cancer cell apoptosis. Anti-PL2L60 Antibody (KAO3) activates complement to mediate tumor cell lysis. Anti-PL2L60 Antibody (KAO3) can be used for the research of lymphoma, breast cancer, lung cancer, cervical cancer, colon cancer, and melanoma[1].

Species: Human

Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Cervical Cancer   Leukemia/Lymphoma/Myeloma   Melanoma  
/
HY-P992051 Anti-CD103 Antibody (hCD103.01A)
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Integrin  
Cancer   Inflammation or Immune System Disease  
/
HY-P10324 TAT-p16
TAT-p16 (p16INK4a peptide) is a peptide mimic of p16INK4a that can induce an early G phase cell cycle arrest in the absence of active cyclin E:Cdk2 complex.
Others  
Cancer  
/
HY-P3756 EPO mimetic peptide-1
EPO mimetic peptide-1 (EMP-1), a 20 amino acid peptide. EPO mimetic peptide-1 stimulates cell proliferation, affects cell cycle and induces the production of reticulocytes in vivo.
Others  
Blood or Cardio-cerebrovascular Disease  
/
HY-P991634 IBI-325
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.

Species: Human

CD73   TNF Receptor   Interleukin Related   IFNAR  
Cancer   Inflammation or Immune System Disease  
/
HY-D1517 FM 2-10
FM 2-10 is a fluorescent dye. FM 2-10 is a less hydrophobic version of FM 1-43 (HY-D1434). FM 2-10 can be used for identifying actively firing neurons and investigating the mechanisms of activity-dependent vesicle cycling.
Fluorescent Dye  
/
HY-P10652 hsBCL9CT-24
hsBCL9CT-24 is a Wnt/β-catenin (b-cat) pathway inhibitor with potent anti-tumor effect. hsBCL9CT-24 reactivates anti-cancer immune response suppressed by the oncogenic Wnt pathway and can be utilized for cancer research.
Wnt   β-catenin  
/
HY-20457G TL8-506 (GMP)
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
Toll-like Receptor (TLR)   Bacterial   Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-P3977 ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat)
ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) is the 3-24 fragment of adrenocorticotropic hormone (ACTH). ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) can be used for research of a variety of diseases, including cancer, immune diseases, cardiovascular disease.
Melanocortin Receptor  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P991464 IBI37G5
IBI37G5 is a human monoclonal antibody (mAb) targeting TNFRSF18/GITR/CD357. IBI37G5 has anti-tumor activity in MC38 and B16F10 mouse tumor models. IBI37G5 can be used in the study of cancer immunity.

Species: Human

TNF Receptor  
Cancer  
/
HY-Y0850U2 PVA (Mw 130000, 87-89% hydrolyzed, ~2700 polymerization)
PVA (Polyvinyl alcohol; Poly(Ethenol)) (Mw 130000, 87-89% hydrolyzed, ~2700 polymerization) is a non-toxic, biodegradable, and highly biocompatible semicrystalline synthetic polymer. PVA (Mw 130000, 87-89% hydrolyzed, ~2700 polymerization) acts as a coating agent to improve tableting performance, and can be cross-linked with sodium trimetaphosphate to prepare tubular vascular grafts or form hydrogels for use as artificial articular cartilage and sustained-release matrices for growth factors. PVA (Mw 130000, 87-89% hydrolyzed, ~2700 polymerization) enhances the redox cycle of iron species in photo-assisted Fenton reactions to simultaneously generate hydrogen peroxide and degrade pollutants, enabling integrated sustainable waste management and water treatment. PVA (Mw 130000, 87-89% hydrolyzed, ~2700 polymerization) is used in the manufacture of biodegradable films and in studies of dry or minimally invasive ex vivo wounds, but cannot form freeze-thaw cross-linked solid sheets for wound dressings.
Biochemical Assay Reagents  
/
HY-P2698 1-Alaninechlamydocin
1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent HDAC inhibitor (IC50=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.

Source: Diheterospora chlamydosporia

HDAC   Apoptosis  
Cancer  
/
HY-P991318 AR20.5
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research.

Species: Human

Mucin  
Cancer  
/
HY-W009362S DL-Isocitric acid-13C4 trisodium salt
DL-Isocitric acid-13C4 (trisodium salt) is a 13C labeled DL-Isocitric acid (trisodium salt) (HY-W009362). DL-Isocitric acid trisodium salt is an endogenous metabolite. DL-Isocitric acid trisodium salt is a substrate in the citric acid cycle. DL-Isocitric acid trisodium salt can be used as a marker for determining the composition of isocitrates in fruit products, including fruit juices.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-W017018S1 L-Ornithine-1,2-13C2 hydrochloride
L-Ornithine-1,2-13C2 hydrochloride is the 13C-labeled L-Ornithine hydrochloride (HY-W017018). L-Ornithine hydrochloride is an orally active CaSR and p38 activator. L-Ornithine hydrochloride inhibits ROS and supports urea cycle function. L-Ornithine hydrochloride can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.
Isotope-Labeled Compounds   CaSR   p38 MAPK   Reactive Oxygen Species (ROS)  
Urogenital Disease   Anxiety or Fear-Related Disease  
/
HY-129283A Goralatide TFA
Goralatide TFA is an inhibitor of cell cycle progression. Goralatide TFA enhances selectivity of hyperthermic purging of human progenitor cells. Goralatide TFA has the potential for the research of leukemia.
Others  
Cancer  
/
HY-P992073 OpSCF
OpSCF (INS1148) is an antibody that specifically binds and inactivates inflammatory stem cell factor (SCF), blocks the positive feedback cycle of chronic inflammation, and aids tissue repair. OpSCF can be used for research related to asthma, pulmonary fibrosis, and interstitial lung disease.

Species: Human

Others  
Asthma  
/
HY-P991150 Ompekimig
Ompekimig is an immunoglobulin monoclonal antibody that targets IL-4, IL-13, IL-33. Ompekimig shows potential for use in immune-mediated inflammatory diseases such as asthma and atopic dermatitis.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-W017018B L-Ornithine monohydrochloride,suitable for cell culture
L-Ornithine monohydrochloride,suitable for cell culture is a CaSR activator and p38 activator suitable for cell culture. L-Ornithine monohydrochloride,suitable for cell culture inhibits ROS and supports urea cycle function. L-Ornithine monohydrochloride,suitable for cell culture can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.
CaSR   p38 MAPK   Reactive Oxygen Species (ROS)  
Urogenital Disease   Anxiety or Fear-Related Disease  
/
HY-P991126 Ciltistotug
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991125 Cenzestotug
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.

Species: Human

TNF Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-P991481A S-531011 (FUT8-KO)
S-531011 (FUT8-KO) is an anti-CCR8 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody. S-531011 (FUT8-KO) can be used for the research of cancer immunity.
CCR  
Cancer   Inflammation or Immune System Disease  
/
HY-P991512 SGN-30
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL).

Species: Human

Apoptosis  
Cancer  
/
HY-P10217 PD-1/PD-L1-IN-42
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P99662 Indusatumab vedotin
Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin (HY-15162). Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis.
Antibody-Drug Conjugates (ADCs)   Guanylate Cyclase   Apoptosis  
/
HY-P10862A AH-D peptide TFA
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-W017018S3 L-Ornithine-d2 hydrochloride
L-Ornithine-d2 hydrochloride is the d2-labeled L-Ornithine hydrochloride (HY-W017018). L-Ornithine hydrochloride is an orally active CaSR and p38 activator. L-Ornithine hydrochloride inhibits ROS and supports urea cycle function. L-Ornithine hydrochloride can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.
Isotope-Labeled Compounds   CaSR   p38 MAPK   Reactive Oxygen Species (ROS)  
Urogenital Disease   Anxiety or Fear-Related Disease  
/
HY-P3486 GADGVGKSAL
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-Y0882S1 Hydroxylamine-d3 hydrochloride
Hydroxylamine-d3 (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride. Hydroxylamine hydrochloride is a selective Monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxylamine hydrochloride is an intermediate of nitrogen cycle in aerobic ammonium oxidizers microorganisms, such as ammonium oxidizing bacteria (AOB), ammonium oxidizing archaea (AOA) and complete ammonium oxidizing bacteria (comammox). Hydroxylamine hydrochloride impacts NO and N2O emissions by aerobic ammonium oxidizers microorganisms and inhibits nitrite oxidizing bacteria (NOB) activity.
Monoamine Oxidase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P10862 AH-D peptide
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50
values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis.
Exosomes   Virus Protease  
Cancer   Infection  
/
HY-P3487 GAGGVGKSA
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-P99834 Crefmirlimab
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.

Species: Human

Transmembrane Glycoprotein  
Lung Cancer  
/
HY-N1420AR Rhamnose monohydrate (Standard)
Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
Reference Standards   Endogenous Metabolite   MMP   Interleukin Related   PKA  
Cancer   Infection   Metabolic or Endocrine Disease  
/
HY-P10424 OPBP-1
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
PD-1/PD-L1  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer  
/
HY-P3488 GADGVGKSA
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
Others  
Cancer   Inflammation or Immune System Disease  
/
HY-44134R Dimethyl 2-oxoglutarate (Standard)
Felypressin (Standard) is the analytical standard of Felypressin. This product is intended for research and analytical applications. Felypressin (PLV-2) is a non-catecholamine vasoconstrictor and a vasopressin 1 agonist. Felypressin is widely used in dental procedures.
Endogenous Metabolite   Reference Standards  
/
HY-P991364 Aldastotug
Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-B1817A Zinc acetate, 99.99% trace metals basis
Zinc (Zinc (II)) acetate, 99.99% trace metals basis is a heme oxygenase 1 (HO-1) activator and apoptosis inducer with cytotoxic and anticancer activities. Zinc acetate, 99.99% trace metals basis enhances HO-1 expression, alters the microRNA profile, and increases the level of caspase-cleaved cytokeratin 18. Zinc acetate, 99.99% trace metals basis also regulates the expression of Cdk2/cyclin E and interferes with cell cycle progression. Zinc acetate, 99.99% trace metals basis effectively inhibits cancer cell proliferation and induces their rapid death, with no significant cytotoxicity to non-tumor tissues. Zinc acetate, 99.99% trace metals basis has been widely used in studies related to hepatocellular carcinoma, prostate cancer, and other conditions.
CDK   Heme Oxygenase (HO)   Apoptosis  
/
HY-113353S Nicotinuric acid-d4
Nicotinuric acid-d4 is the 4-labeled Nicotinuric acid (HY-113353). Nicotinuric acid is an acylglycine and the major catabolite of nicotinic acid (HY-B0143). Its urinary levels correlate with body mass index, blood pressure, blood lipid parameters, and high-sensitivity C-reactive protein. Nicotinuric acid participates in coenzyme-related activities including glycolysis, gluconeogenesis, the citric acid cycle, oxidation, and long-chain fatty acid synthesis in various tissues. Nicotinuric acid is associated with the progression of metabolic syndrome to diabetes and atherosclerotic cardiovascular disease[1]
Isotope-Labeled Compounds   Drug Metabolite  
Glucose Metabolism   Atherosclerosis and Inflammation  
/
HY-W017018S5 L-Ornithine-15N2 hydrochloride
L-Ornithine-15N2 hydrochloride is the 15N-labeled L-Ornithine (hydrochloride) (HY-W017018). L-Ornithine hydrochloride is an orally active CaSR and p38 activator. L-Ornithine hydrochloride inhibits ROS and supports urea cycle function. L-Ornithine hydrochloride can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.
Isotope-Labeled Compounds   CaSR   p38 MAPK   Reactive Oxygen Species (ROS)  
Urogenital Disease   Anxiety or Fear-Related Disease  
/
HY-132260 Naratuximab emtansine
Naratuximab emtansine (IMGN529) is a CD37-targeted ADC consisting of a humanized IgG1 mAb coupled to the microtubule disruptor DM1. Naratuximab emtansine has high affinity and specificity for CD37, allowing ADC internalization, processing and intracellular release of DM1. Due to its ability to disrupt microtubule assembly, DM1 can subsequently induce cell cycle arrest and apoptosis.
Antibody-Drug Conjugates (ADCs)   Apoptosis  
/
HY-P11058 OVA(250-264)
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
MHC  
/
HY-W017018S L-Ornithine-d6 hydrochloride
L-Ornithine-d6 hydrochloride is the d6-labeled L-Ornithine hydrochloride (HY-W017018). L-Ornithine hydrochloride is an orally active CaSR and p38 activator. L-Ornithine hydrochloride inhibits ROS and supports urea cycle function. L-Ornithine hydrochloride can be used to study kidney diseases involving proximal tubular cell damage caused by oxidative stress or crystallopathy, as well as research related to anxiety disorders.
Isotope-Labeled Compounds   CaSR   p38 MAPK   Reactive Oxygen Species (ROS)  
Urogenital Disease   Anxiety or Fear-Related Disease  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-P10950A PD-L1 inhibitory peptide TFA
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
PD-1/PD-L1   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-P990042 Gotistobart
Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer  
/
HY-P990690 Volrustomig
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1+ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1+ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer.

Species: Human

PD-1/PD-L1   CTLA-4  
Gastric Cancer   Liver Cancer   Cervical Cancer   Non-Small Cell Lung Cancer  
/
HY-W020958 Ru(acac)3
Ru (acac) 3 (Tris (acetylacetonato) ruthenium (III)) is a caspase-3 activator and Apoptosis inducer. Ru (acac) 3 exerts growth inhibitory effects on various cell lines in vitro by inhibiting DNA/RNA synthesis and inducing mild reversible S-phase cell cycle arrest. Ru (acac) 3 is commonly used in research related to ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other fields.
Caspase   Apoptosis  
Cervical Cancer   Ovarian Cancer  
/
HY-W020955 Triphenylphosphinechlorogold
Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I)) is a gold complex, Apoptosis inducer, and catalyst. Triphenylphosphinechlorogold exhibits high LOX inhibitory activity. Triphenylphosphinechlorogold induces cell cycle arrest and apoptosis. Triphenylphosphinechlorogold catalyzes the peroxidation of linoleic acid. A weak interaction exists between Triphenylphosphinechlorogold and DNA. Triphenylphosphinechlorogold displays antiproliferative activity against breast cancer cells.
Biochemical Assay Reagents   Apoptosis   DNA Alkylator/Crosslinker   Lipoxygenase  
Breast Cancer  
/
HY-P990789 Anti-Mouse CTLA-4 Antibody (9H10)
Anti-Mouse CTLA-4 Antibody (9H10) is a kind of syrian hamster IgG antibody inhibitor, targeting to CTLA-4. Anti-Mouse CTLA-4 Antibody (9H10) binds mouse CTLA-4 and blocks the interaction between CTLA-4 and its ligand. Anti-Mouse CTLA-4 Antibody (9H10) shows potent anti-tumor effect in various tumor models, such as breast and colon cancer.

Species: Mouse

CTLA-4  
Breast Cancer   Prostate Cancer  
/
HY-127137 Adenylosuccinic acid
Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD).
Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-164729 FZ-AD005
FZ-AD005 is a DLL3-targeting antibody-drug conjugate (ADC) with high selectivity, composed of the anti-DLL3 antibody FZ-A038 (HY-P990896), a dipeptide linker (Val-Ala), and DXd (HY-13631D). The Kd value of FZ-AD005 for human DLL3 ranges from 13.29 to 58.3 pmol/L. After binding to DLL3 on the cell surface, FZ-AD005 mediates endocytosis, and the payload DXd is released via cleavage by lysosomal cathepsins. DXd inhibits topoisomerase TopI to induce double-strand DNA breaks, cell cycle arrest and apoptosis, and FZ-AD005 exhibits bystander killing activity against adjacent DLL3-negative cells. FZ-AD005 shows stable circulation in vivo, has good tolerance and acceptable pharmacokinetic profiles in rats and cynomolgus monkeys, and effectively inhibits the growth of DLL3-expressing tumor cells. FZ-AD005 serves as a promising candidate molecule for research on small cell lung cancer and human neuroendocrine prostate cancer.
Antibody-Drug Conjugates (ADCs)   Topoisomerase   Apoptosis  
Prostate Cancer   Small Cell Lung Cancer  
/
HY-W017464 NAPQI
NAPQI is the toxic metabolite of Acetaminophen (HY-66005). NAPQI is also an inhibitor of enzymes in the vitamin K cycle. NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency, excess NAPQI reacts with cysteine residues in proteins, causing cell death and toxicity in the liver.
Drug Metabolite   Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P99175 KWAR 23
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Species: Human

CD47  
Cancer  
/
HY-113131A Dihydroxyacetone phosphate hemimagnesium hydrate
Dihydroxyacetone phosphate (DHPA) hemimagnesium hydrate, a derivative of Dihydroxyacetone (DHA), is an important intermediate that participates in key pathways including glycolysis, lipid biosynthesis, and the plant Calvin cycle. Dihydroxyacetone phosphate hemimagnesium hydrate can be used as a substrate and metabolic marker in biochemical research.
Endogenous Metabolite   Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-N12634 Pregnant mare serum gonadotropin
Pregnant mare serum gonadotropin (PMSG) is a gonadotropin used to promote follicular development and ovulation in animals. PMSG exerts its regulatory effects by stimulating changes in blood hormones, gonadotropins, and cytoplasmic estradiol receptors in the anterior pituitary and hypothalamus. PMSG is commonly used in livestock to improve reproductive efficiency and can also be utilized for research on estrous cycle regulation.

Source: horse

Endogenous Metabolite  
Metabolic or Endocrine Disease  
/
HY-P991097 Pumitamig
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.

Species: Human

VEGFR   PD-1/PD-L1  
Ovarian Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P9918 Tremelimumab
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.

Species: Human

CTLA-4  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P702779 CDK1 Protein, Human (Active, sf9)
The CDK1/CDC2-cyclin-B complex is a key regulator in the cell cycle. It plays an important role in cell division and development and regulates a variety of cellular activities, including chromosome segregation, nuclear membrane rupture, cytokinesis, etc. The activity of CDK1 is regulated by a variety of phosphorylation and dephosphorylation, thereby controlling the progression of the cell cycle and the DNA repair process. CDK1 Protein, Human (sf9) is the recombinant human-derived CDK1, expressed by Sf9 insect cells, with tag-free. The total length of CDK1 Protein, Human (sf9) is 297 a.a..

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin Dependent Kinase 1 (CDK1)

/
HY-P703597 CDC7 Protein, Human (His)
CDC7 Protein, Human (His) is the recombinant human-derived CDC7, expressed by E. coli , with His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins Other Kinases CDC7

/
HY-P703039 CDK20 Protein, Mouse (sf9, GST)
CDK20 Protein, Mouse (sf9, GST) is the recombinant mouse-derived CDK20, expressed by Sf9 insect cells , with GST labeled tag.

Species: Mouse; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK CDK20/CCRK

/
HY-P75364 CDC37 Protein, Human (sf9, GST)
The CDC37 protein is a co-chaperone that binds multiple kinases and promotes their interaction with the Hsp90 complex, resulting in stability and enhanced activity. CDC37 Protein, Human (sf9, GST) is the recombinant human-derived CDC37 protein, expressed by Sf9 insect cells , with C-GST labeled tag.

Species: Human; Source: Sf9 insect cells

/
HY-P75362 CDC37 Protein, Mouse (sf9, His-GST)
The CDC37 protein is a co-chaperone that binds to kinases and promotes their interaction with Hsp90 complexes, thereby stabilizing and activating them. It inhibits the ATPase activity of HSP90AA1. CDC37 Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived CDC37 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Species: Mouse; Source: Sf9 insect cells

/
HY-P75363 CDC37 Protein, Mouse (sf9)
The CDC37 protein is a co-chaperone that binds to kinases and promotes their interaction with Hsp90 complexes, thereby stabilizing and activating them. It inhibits the ATPase activity of HSP90AA1. CDC37 Protein, Mouse (sf9) is the recombinant mouse-derived CDC37 protein, expressed by Sf9 insect cells, with tag free.

Species: Mouse; Source: Sf9 insect cells

/
HY-P701252 RPRD1B Protein, Human (HEK293, N-His)
RPRD1B, is a necessary scaffolding protein that maintains genetic integrity by regulating resolution of R-loops at both the transcription termination and DNA double-strand break (DSB) repair levels. In endometrial cancers, RPRD1B accelerates cell cycle through up-regulating Cyclin D1, CDK4, and CDK6. In addition, RPRD1B enhancse transcription of CCND1 and promotes cell proliferation by interacting with RNA polymerase II. RPRD1B enhances the β-Catenin·TCF4 transcriptional activity in response to Wnt signaling. RPRD1B Protein, Human (HEK293, N-His) is the recombinant human-derived RPRD1B protein, expressed by HEK293 , with N-6*His labeled tag.

Species: Human; Source: HEK293

/
HY-P702920 CDK11A-CCND3 Protein, Human (sf9, GST)
CDK11A-CCND3 Protein, Human (sf9, GST) is the recombinant human-derived CDK11A-CCND3, expressed by Sf9 insect cells , with N-GST labeled tag. ,

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK CDK11A/CDC2L2

/
HY-P703057 CDK11A Protein, Human (sf9, GST)
CDK11A Protein, Human (sf9, GST) is the recombinant human-derived CDK11A, expressed by Sf9 insect cells , with GST labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK CDK11A/CDC2L2

/
HY-P704540 CDC42 Protein, Human (Active, GST-His)
CDC42 is a plasma membrane-associated small GTPase that regulates cellular responses by cycling between an active GTP-bound state and an inactive GDP-bound state. It participates in epithelial cell polarization, regulates the attachment of spindle microtubules to kinetochores, affects cell migration, and plays a key role in the formation of filopodia. CDC42 Protein, Human (Active, GST-His) is the recombinant human-derived CDC42 protein, expressed by E. coli, with N-His and N-GST labeled tag.

Species: Human; Source: E. coli

/
HY-P80617 Chk1 Antibody
Chk1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Chk1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P86862 EPCR Antibody (YA6555)
EPCR Antibody (YA6555) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EPCR.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P83423 CDC40 Antibody (YA3168)
CDC40 Antibody (YA3168) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDC40.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P82864 CDCA5 Antibody (YA2609)
CDCA5 Antibody (YA2609) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDCA5.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P810856 CDC20 Antibody
CDC20 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to CDC20.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-P82384 CEND1 Antibody (YA2129)
CEND1 Antibody (YA2129) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CEND1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83028 CDC123 Antibody (YA2773)
CDC123 Antibody (YA2773) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDC123.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84958 CDC123 Antibody (YA4650)
CDC123 Antibody (YA4650) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDC123.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84958A CDC123 Antibody (YA4650)(PBS only)
CDC123 Antibody (YA4650) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDC123.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85570 Rad9 Antibody (YA5262)
Rad9 Antibody (YA5262) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Rad9.

Host: Mouse; Reactivity: Human, Mouse, Rat, Monkey

Monoclonal Antibodies Primary Antibodies

/

Keywords

Cancer Immunotherapy | Cancer-Immunity Cycle